Interpace Biosciences (IDXG) Tops Q1 EPS by 29c

Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.10, $0.29 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65
• Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c